ClinicalTrials.gg
RecruitingNCT07152678BRIGHT-ESCCUpdated Sep 3, 2025

Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Nivolumab (240 mg) and Brachytherapy in Esophageal Cancer and Esophageal Squamous Cell Carcinoma, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-03.

Primary conditionEsophageal Squamous Cell CarcinomaRegistry: Esophageal NeoplasmsReclassifiedWhy we changed it
Registry
Esophageal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Esophageal Squamous Cell Carcinoma
Why
  1. The study's listed conditions name Esophageal Squamous Cell Carcinoma, a narrower term within Esophageal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Taiwan University Hospital · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma — 2 open to participants now, 3 under way, none of them phase 3. Nivolumab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
3rd of 10
60 · median 46
Started
2025
the only one that year
Phase 2
7 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
2 of 10
National Taiwan University Hospital

Among the 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 2, and was the 10th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

2 of the 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing nivolumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if adding high-dose-rate (HDR) brachytherapy can improve outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who have already received external beam radiotherapy (EBRT), chemotherapy, and the immune therapy drug nivolumab.

The main questions it aims to answer are:

  • Does HDR brachytherapy reduce the chance of the cancer coming back in the esophagus or nearby areas within 12 months?
  • What side effects or safety issues occur when HDR brachytherapy is given after EBRT, chemotherapy, and nivolumab?

Participants will:

  • Receive 1-2 sessions of HDR brachytherapy delivered through a thin tube placed inside the esophagus, within three weeks after starting nivolumab.
  • Continue nivolumab and be monitored with regular follow-up visits, imaging tests, and blood samples to check treatment response and safety.
Read the detailed description

This is a single-arm, phase II clinical trial designed to evaluate the efficacy and safety of high-dose-rate (HDR) esophageal brachytherapy in combination with external beam radiotherapy (EBRT), chemotherapy, and immune checkpoint inhibition with nivolumab in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

Eligible patients include those with stage III-IVB ESCC who have previously received EBRT with concurrent platinum-fluoropyrimidine chemotherapy and who have initiated nivolumab therapy. HDR brachytherapy (5-12 Gy in 1-2 fractions) will be administered within three weeks following the start of nivolumab.

The primary endpoint is the 12-month cumulative incidence of locoregional failure. Secondary endpoints include overall survival, progression-free survival, overall response rate, disease control rate, safety and tolerability, tube-dependence-free survival, tumor-infiltrating lymphocyte density, and circulating tumor DNA dynamics.

The rationale for this trial is that HDR brachytherapy offers precise dose escalation directly to the esophageal tumor, which may improve locoregional control beyond EBRT alone. In addition, the combination of localized high-dose irradiation with systemic immune checkpoint inhibition has the potential to enhance antitumor immunity, thereby improving clinical outcomes in this high-risk population.

03

Conditions studied

  • Esophageal Cancer
  • Esophageal Squamous Cell Carcinoma

Browse trials for

Keywords

  • Esophageal squamous cell carcinoma
  • Brachytherapy
  • Immune checkpoint inhibitor
  • Nivolumab
  • Radiotherapy
  • Locoregional control
04

In context

Esophageal Squamous Cell Carcinoma Reclassified

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

This study's planned enrollment of 60 is close to the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.

Browse Esophageal Squamous Cell Carcinoma studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Compared within Esophageal Squamous Cell Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Esophageal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18-85 years, with performance 0-2.
  • Locally-advanced esophageal squamous cell carcinoma with clinical stage III, IVA with proven.
  • Prior treatment with EBRT (40-50.4 Gy in 20-28 fractions) and platinum + fluoropyrimidine chemotherapy, with residual or progressive disease, and deemed inoperable or unable to undergo surgery.
  • No prior exposure to ICIs and had received first cycle of nivolumab after CCRT.
  • Biopsy proven with [tumor cell (TC) ≥ 1%]
  • Required at least one measurable or non- per (RECIST), version 1.1.
  • Patients with limited stage IVB disease (e.g., non-visceral lymph node ) may be enrolled if the primary tumor is locally dominant and suitable for brachytherapy, based on investigator's discretion.

Exclusion criteria

Exclusion Criteria:

  • Current or past history of severe to any other antibody products.
  • Patients with any in the brain or meninx that is symptomatic or requires treatment.
  • Patients with active, known or suspected disease
  • Stenosis of esophageal lumen that cannot performed brachytherapy
  • Involvement of tracheal mucosa or bronchial mucosa.
  • The distribution of the lesions of interest exceeds 10 cm range.
  • The patient is participating in other interventional clinical trials associated with immunotherapy.
  • The patient is scheduled to undergo esophagostomy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Add-on of intraluminal brachytherapy with applicator

    Brachytherapy protocol starts within 3 weeks after first cycle of immunotherapy administered (This is "week 1"). High-dose-rate (HDR) 5-6 Gy per fraction is delivered to GTV of esophageal tumor(s), second treatment if applicable will be finished within 2 weeks after the first fraction, a total of 5-12 Gy in 1-2 fractions will be delivered. GTV coverage D90 should equal 100% of prescription. It is NOT allowed to give concurrent chemotherapy on the days of HDR brachytherapy.

    Drug: Nivolumab (240 mg) · Radiation: Brachytherapy

Interventions

  • DrugNivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After the first cycle of nivolumab administered in the screening phase (1st cycle), nivolumab in the study phase was administered intravenously over 30 minutes at a dose of 240 mg every 2 weeks for at least 2 doses, with 1 cycle after to first brachytherapy (2nd cycle), and 1 more cycle after to second brachytherapy (3rd cycle) if feasible. (each cycle was 2 weeks), until disease progression assessed by the investigator per RECIST version 1.1, or unacceptable toxicity.

  • RadiationBrachytherapy

    Brachytherapy protocol starts within 3 weeks after first cycle of nivolumab was administered. After brachytherapy applicator placement, CT simulation scan(s) with dummy source in place will be done for further planning procedure, including adjustment of the applicator and 3D treatment planning. High-dose-rate (HDR) 5-Gy per fraction is delivered to the gross tumor volume (GTV) of esophageal tumor(s), second treatment if applicable will be finished within 2 weeks after the first fraction, a total of 5-12 Gy in 1-2 fractions will be delivered. GTV coverage D90 should equal 100% of prescription. Efforts should be made to spare the adjacent normal organ and to avoid hot spot on normal esophageal mucosa. It is NOT allowed to give concurrent chemotherapy on the days of HDR brachytherapy.

07

What researchers measure

Primary outcomes

  1. Cumulative incidence of locoregional failure at 12 months

    The proportion of patients who develop tumor recurrence or persistence in the esophagus or regional lymph nodes, as assessed by central review using endoscopy, CT and/or PET according to RECIST v1.1 and iRECIST criteria.

    Time frame: 12 months from initiation of HDR brachytherapy

Secondary outcomes

  1. Overall Response Rate (ORR)

    Percentage of patients achieving complete response or partial response as best overall response, assessed by investigators per RECIST v1.1 and iRECIST.

    Time frame: Up to 24 months

  2. Overall Survival (OS)

    Time from enrollment to death from any cause.

    Time frame: Up to 24 months

  3. Progression-Free Survival (PFS)

    Time from enrollment to first documented tumor progression or death, whichever occurs first.

    Time frame: Up to 24 months

  4. Disease Control Rate (DCR)

    Percentage of patients achieving complete response, partial response, or stable disease, as best overall response per RECIST v1.1/iRECIST.

    Time frame: Up to 24 months

  5. Duration of Response (DoR)

    Time from the first documentation of complete or partial response to the first documented tumor progression or death.

    Time frame: Up to 24 months

  6. Cumulative incidence of distant failure

    Proportion of patients developing new distant metastases over the study period, accounting for competing risks.

    Time frame: Up to 24 months

  7. Safety and tolerability

    Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and immune-related adverse events, graded according to CTCAE v5.0.

    Time frame: From first study treatment through 90 days after last dose and up to 24 months for late effect

  8. Tube-dependence-free survival

    Proportion of patients who remain alive without requiring feeding tube support (e.g., nasogastric or jejunostomy tube) for nutrition.

    Time frame: Up to 24 months

  9. Circulating tumor DNA (ctDNA) dynamics

    Change in ctDNA levels measured at baseline and during follow-up as an indicator of treatment response and disease progression.

    Time frame: Baseline and up to 24 months

  10. Tumor-infiltrating lymphocyte (TIL) density

    Change in tumor-infiltrating lymphocyte density in tumor biopsy samples collected before and after HDR brachytherapy.

    Time frame: Baseline to up to 12 weeks after HDR brachytherapy

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 24 months is below that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 3, 2025
StartEst.
Sep 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07152678
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Sep 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 3, 2025

Study contacts

Yen-Ting Liu, MD
Contact
nickliucool@ntuh.gov.tw
+886-2-33663366 ext. 24130
Yen-Ting Liu, MD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion